Bispecific chimeric antigen receptor and use thereof

By designing a bispecific chimeric antigen receptor targeting CD44 and CD133, the problem of insufficient target selection and immune regulation in the treatment of glioma and brain metastases was solved, achieving highly efficient killing and growth inhibition of CD44/CD133 positive tumor cells and prolonging the survival of tumor-bearing mice.

WO2026233184A1PCT designated stage Publication Date: 2026-11-12BEIJING NEUROSURGICAL INST +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/093751
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-04-29
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing chimeric antigen receptor T-cell therapies for glioma and brain metastases have limited target selection and insufficient immunomodulatory capacity, resulting in poor treatment outcomes, especially poor targeting of glioma stem cells and high recurrence rates.

Method used

A bispecific chimeric antigen receptor was designed, comprising CD44 and CD133 binding domains, a hinge region, a transmembrane domain, a co-stimulatory domain, and a CD3ζ signaling domain. By genetically engineering immune cells, they were able to simultaneously target CD44 and CD133 antigens, thereby enhancing the killing and activation capabilities of immune cells.

Benefits of technology

It significantly enhanced the binding ability and killing effect on CD44/CD133 positive tumor cells, promoted the release of cytokines IFN-γ and Granzyme B, improved the tumor growth inhibition effect, and significantly prolonged the survival of tumor-bearing mice in in vivo models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026093751_12112026_PF_FP_ABST
    Figure CN2026093751_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A bispecific chimeric antigen receptor, comprising CD44 and CD133 binding domains, a hinge region, a transmembrane domain, one or more costimulatory domains, and a CD3ζ signaling domain, wherein the CD44 binding domain comprises amino acid sequences as shown in SEQ ID NOs: 1-6, and the CD133 binding domain comprises amino acid sequences as shown in SEQ ID NOs: 7-12.
Need to check novelty before this filing date? Find Prior Art

Description

A bispecific chimeric antigen receptor and its applications Technical Field

[0001] This invention belongs to the field of biopharmaceutical technology, specifically relating to a bispecific chimeric antigen receptor T-cell immunotherapy targeting human CD44 and CD133 and its application. Background Technology

[0002] In recent years, with the popularization of cancer screening, the emphasis on early diagnosis, and the advancement of medical treatments, the overall survival rate of cancer patients worldwide has shown a continuous upward trend. However, malignant tumors remain one of the most serious public health problems globally, ranking among the leading causes of death in both China and the United States, and the incidence and mortality rates of some cancers have not been effectively controlled. Traditional cancer treatments such as radiotherapy, chemotherapy, and targeted therapy typically target tumor cells themselves. Although they show significant efficacy in the early stages of cancer treatment, problems such as tumor recurrence and drug resistance become increasingly prominent as the disease progresses and treatment time lengthens. Therefore, developing more effective anti-tumor drugs and new treatment methods is a matter of close concern for researchers. In recent years, chimeric antigen receptor T cell (CAR-T) therapy has received considerable attention in the field of cancer research and clinical treatment as an emerging immunotherapy approach. Since 2017, the US FDA has approved six CAR-T cell products for the treatment of hematological malignancies. CD19 CAR-T cell therapy is indicated for large B-cell lymphoma, acute B-lymphoblastic leukemia, mantle cell lymphoma, and follicular lymphoma; BCMACAR-T cell therapy has been approved for the treatment of multiple myeloma. Its significant efficacy has led to its rapid adoption as a first- or second-line treatment. The success of CAR-T cell therapy in treating hematological malignancies has demonstrated the feasibility and enormous application potential of this innovative therapy, sparking a wave of research and development of CAR-T cell therapies for solid tumors both domestically and internationally, aiming to provide cancer patients with more treatment options. However, in most solid tumors, the lack of ideal target antigens and the presence of complex immunosuppressive factors in the tumor microenvironment affect the therapeutic efficacy of CAR-T cells.

[0003] Gliomas are the most common malignant brain tumors, accounting for about 45% of intracranial tumors. They are highly invasive and lethal. In my country, the annual incidence rate of gliomas is 5 to 8 per 100,000, and the 5-year mortality rate is second only to pancreatic cancer and lung cancer among all cancers.

[0004] Standard treatment for newly diagnosed glioblastoma (nGBM) includes surgery, radiotherapy, and chemotherapy. Tumors typically recur within 6-8 months of initial surgical resection, with a median overall survival (MOS) of 15-17 months and a 5-year survival rate generally less than 5%. Currently, there are no effective treatments or regimens for glioma patients who relapse after standard treatment. The limitations of current treatment methods and the lack of emerging therapies are major obstacles to improving the prognosis of glioma patients.

[0005] Brain metastases, also known as intracranial metastases, refer to tumor cells originating in other parts of the body that have spread to the brain. They account for 3.5%-10% of all intracranial tumors, and are commonly found in lung cancer, melanoma, and breast cancer. The tumors can be single or multiple, and they develop rapidly with a short course. Clinical manifestations mainly include localized symptoms in the brain tissue and symptoms of invasion and compression of adjacent tissues; the primary lesion and systemic cachexia are also present. Treatment outcomes are generally poor.

[0006] Cellular immunotherapy for tumors has become a hot research topic as a novel treatment strategy. Chimeric antigen receptor (CAR) T cells are genetically engineered molecules expressed on T cells, composed of antigen-binding domains, transmembrane domains, and intracellular signal transduction domains. They can target and recognize target antigens on the surface of tumor cells, thereby killing tumor cells. With the approval of multiple CAR-T therapies for the treatment of hematologic malignancies, CAR-T therapy has made significant progress in tumor treatment. To date, several CAR-T therapies have entered clinical practice for the treatment of gliomas.

[0007] The core issue of CAR-T therapy remains target selection, and the key challenge is regulating cell activity, balancing cytotoxicity and immunomodulation. Due to the heterogeneity of gliomas, the application of single-target CAR-T cells in glioma treatment is severely limited. Since glioma stem cells do not exhibit heterogeneity and play a crucial role in tumor treatment resistance, recurrence, and invasion, targeting glioma stem cells offers a novel approach to circumvent this tumor heterogeneity. Increasing evidence suggests that stem cell markers CD133 and CD44 indicate molecular subtypes of gliomas. CD44 is primarily expressed in the mesenchymal subtype, while CD133 is mainly expressed in the neuronal subtype; these two are mutually exclusive in expression and play important roles in glioma growth and invasion, making them ideal targets for developing glioma therapies.

[0008] In 2022, RU2020128309(A) disclosed a gene sequence that includes a pairwise chimeric receptor encoding CD44 and CD133 tumor antigens, which can be used to treat malignant tumors, especially glioblastoma.

[0009] Based on existing technologies, this invention provides novel CD44 and CD133 sequences, their connection structures, and co-stimulatory domains, which have superior affinity and therapeutic effects compared to existing technologies. Summary of the Invention

[0010] The present invention provides a bispecific chimeric antigen receptor comprising a CD44 and CD133 binding domain, a hinge region, a transmembrane domain, one or more co-stimulatory domains, and a CD3ζ signaling domain.

[0011] The CD44 binding domain includes:

[0012] The amino acid sequence of the heavy chain complementarity-determining region HCDR1 is shown in SEQ ID NO: 1;

[0013] The amino acid sequence of the heavy chain complementarity-determining region HCDR2 is shown in SEQ ID NO: 2;

[0014] The amino acid sequence of the heavy chain complementarity-determining region HCDR3 is shown in SEQ ID NO: 3;

[0015] The amino acid sequence of the light chain complementarity-determining region LCDR1 is shown in SEQ ID NO: 4;

[0016] The amino acid sequence of the light chain complementarity-determining region LCDR2 is shown in SEQ ID NO: 5;

[0017] The amino acid sequence of the light chain complementarity-determining region LCDR3 is shown in SEQ ID NO: 6;

[0018] The CD133 binding domain includes:

[0019] The amino acid sequence of the heavy chain complementarity-determining region HCDR1 is shown in SEQ ID NO: 7;

[0020] The amino acid sequence of the heavy chain complementarity-determining region HCDR2 is shown in SEQ ID NO: 8;

[0021] The amino acid sequence of the heavy chain complementarity-determining region HCDR3 is shown in SEQ ID NO: 9;

[0022] The amino acid sequence of the light chain complementarity-determining region LCDR1 is shown in SEQ ID NO: 10;

[0023] The amino acid sequence of the light chain complementarity-determining region LCDR2 is shown in SEQ ID NO: 11;

[0024] The amino acid sequence of the light chain complementarity-determining region LCDR3 is shown in SEQ ID NO: 12.

[0025] Furthermore, the amino acid sequence of the VH region of CD44 is shown in SEQ ID NO: 13. The amino acid sequence of the VL region of CD44 is shown in SEQ ID NO: 14.

[0026] Furthermore, the amino acid sequence of the VH region of CD133 is shown in SEQ ID NO: 15. The amino acid sequence of the VL region of CD133 is shown in SEQ ID NO: 16.

[0027] Among them, the VH and VL regions of CD44, the VH and VL regions of CD133, and the connection between CD44 and CD133 are all made using a linker.

[0028] The linker is a commonly used flexible linker, including but not limited to (GGGGS)n, (G)n or other modified flexible linkers.

[0029] Preferably, the linkers in this application are all of the (GGGGS)n type.

[0030] Preferably, n is 2 or 3.

[0031] Most preferably, the linkers in this application all use the linker with the amino acid sequence shown in SEQ ID NO: 17.

[0032] Furthermore, in the bispecific chimeric antigen receptor described in this invention, the hinge region is the CD8α hinge region, and its amino acid sequence is shown in SEQ ID NO: 19.

[0033] Furthermore, in the bispecific chimeric antigen receptor described in this invention, the transmembrane domain is the CD8α transmembrane region, the amino acid sequence of which is shown in SEQ ID NO: 20.

[0034] Furthermore, in the bispecific chimeric antigen receptor described in this invention, the co-stimulatory domain is CD28, and its amino acid sequence is shown in SEQ ID NO: 21.

[0035] Preferably, in the bispecific chimeric antigen receptor of the present invention, the co-stimulatory domain further includes the full-length sequence of IL-7Rα, or a truncated portion thereof.

[0036] IL-7 is a 25 kDa soluble secretory protein encoded by the IL7 gene. Its receptor (IL-7R) is a heterodimeric complex composed of IL-7Rα and γ chains. The IL-7Rα chain (IL-7RA; also known as CD127) is a type 1 membrane glycoprotein composed of an extracellular domain, a transmembrane region, and an intracellular portion.

[0037] The truncated portion of IL-7Rα described in this invention refers to the intracellular portion of IL-7Rα.

[0038] The full-length amino acid sequence of IL-7Rα is shown in SEQ ID NO: 22. The truncated amino acid sequence of IL-7Rα is shown in SEQ ID NO: 23.

[0039] Preferably, the co-stimulatory domain of the bispecific chimeric antigen receptor of the present invention further includes a truncated portion of IL-7Rα.

[0040] The amino acid sequence of the CD3ζ signaling domain of the bispecific chimeric antigen receptor described in this invention is shown in SEQ ID NO: 24.

[0041] Most preferably, the bispecific chimeric antigen receptor of the present invention has an amino acid sequence as shown in SEQ ID NO: 28, or an amino acid sequence having 95% to 99% identity with it.

[0042] Furthermore, the bispecific chimeric antigen receptor of the present invention further includes a signal peptide sequence, wherein the signal peptide sequence is shown in SEQ ID NO: 31.

[0043] The present invention also provides a nucleic acid molecule that encodes the bispecific chimeric antigen receptor described in the present invention, the nucleotide sequence of which is shown in SEQ ID NO: 35.

[0044] The present invention also provides an expression vector comprising the nucleic acid molecule described herein.

[0045] The expression vector is selected from any one of lentiviral expression vectors, retroviral expression vectors, adenovirus expression vectors, adeno-associated virus expression vectors, DNA vectors, RNA vectors, and plasmids.

[0046] The present invention also provides a genetically engineered immune cell that expresses the bispecific chimeric antigen receptor described in the present invention.

[0047] The genetically engineered immune cells described in this invention may be selected from immune cells cultured and differentiated from T lymphocytes, NK cells, hematopoietic stem cells, pluripotent stem cells or embryonic stem cells, with T lymphocytes being the most preferred.

[0048] The present invention also provides a pharmaceutical composition comprising the bispecific chimeric antigen receptor described in the present invention, or the nucleic acid molecule described in the present invention, or the expression vector described in the present invention, or the genetically engineered immune cell described in the present invention.

[0049] Finally, this invention also provides the application of the bispecific chimeric antigen receptor described in this invention, or the nucleic acid molecule described in this invention, or the expression vector described in this invention, or the genetically engineered immune cells described in this invention in the preparation of drugs for treating anti-tumor diseases.

[0050] The tumor is a CD44 and / or CD133 positive tumor.

[0051] Specifically, the tumors described in this invention include, but are not limited to, glioma, renal cell carcinoma, pancreatic cancer, prostate cancer, melanoma, epidermal cancer, breast cancer, lung cancer, ovarian cancer, cervical cancer, osteosarcoma, liver cancer, colon cancer, and metastatic tumors.

[0052] Preferably, the tumor is a glioma.

[0053] Preferably, the tumor is a brain metastasis.

[0054] The brain metastases include, but are not limited to, brain metastases from melanoma, lung cancer, and breast cancer.

[0055] The beneficial effects of this invention are as follows:

[0056] The bispecific chimeric antigen receptor of this invention exhibits strong binding affinity to CD44 / CD133-positive tumor cells, demonstrating significant killing effects on single-target-positive or dual-target-positive tumor cells. Furthermore, upon stimulation by target cells, this bispecific chimeric antigen receptor is activated, significantly promoting the release of cytokines IFN-γ and Granzyme B in a time- and concentration-dependent manner. Simultaneously, it continuously induces T cell proliferation upon target cell stimulation, exhibiting strong proliferative capacity. In vivo administration significantly inhibits the growth of single-target-positive or dual-target-positive tumors, demonstrating good tolerability. Attached Figure Description

[0057] Figure 1. Schematic diagram of the molecular structures of each group in this invention;

[0058] Figure 2 shows a comparison of cell binding activities between P131 scFv-hFc and P134 scFv-hFc;

[0059] Figure 3 shows the inhibitory effect of P134 CAR-T cells and P131 CAR-T cells on the in vitro proliferation of H_CD133 Luc U-87MG cells;

[0060] Figure 4 shows the inhibitory effect of P134 CAR-T cells and P131 CAR-T cells on the in vitro proliferation of Luc-U87 MG cells;

[0061] Figure 5 shows the binding activity of P134 scFv-hFc with CD44&CD133 positive cells H_CD133 Luc U-87MG or CD44&CD133 negative cells MCF-7;

[0062] Figure 6 shows the killing ability of each group of CAR-T cells against CD44&CD133 positive glioma cells H_CD133Luc U-87MG;

[0063] Figure 7 shows that after CAR-T cells in each group were activated by target cell stimulation, the release of cytokine IFN-γ was promoted.

[0064] Figure 8 shows that after CAR-T cells in each group were activated by target cell stimulation, the release of the cytokine Granzyme B was promoted.

[0065] Figure 9 shows the inhibitory effect of P134 CAR-T cells and P137 Mock T cells on the in vitro proliferation of H_CD133 Luc U-87MG cells;

[0066] Figure 10 shows the time-effect relationship of the release of cytokine IFN-γ after activation of P134 CAR-T cells and P137 Mock T cells by target cell stimulation.

[0067] Figure 11 shows the time-effect relationship of the promotion of Granzyme B release by P134 CAR-T cells and P137 Mock T cells after activation by target cell stimulation.

[0068] Figure 12 shows that P134 CAR-T cells inhibit tumor growth in a human glioma U-87MG-GFP-Luc cell NPG mouse orthotopic xenograft model;

[0069] Figure 13 shows that P134 CAR-T cells prolong the survival of tumor-bearing mice in the orthotopic xenograft model of human glioma U-87MG-GFP-Luc cells in mice;

[0070] Figure 14 shows the effect of P134 CAR-T cells on the body weight changes of tumor-bearing mice in the NPG mouse orthotopic xenograft model of human glioma U-87MG-GFP-Luc cells;

[0071] Figure 15 shows that P134 CAR-T cells inhibit tumor growth in a human glioma H_CD133 U-87MG-Luc cell NPG mouse orthotopic xenograft model;

[0072] Figure 16 shows the effect of P134 CAR-T cells on the body weight changes of tumor-bearing mice in the NPG mouse orthotopic xenograft model of human glioma U-87MG-GFP-Luc cells;

[0073] Figure 17 shows that P134 CAR-T cells inhibit tumor growth in a mouse orthotopic brain xenograft model of melanoma A375 cells NPG cells;

[0074] Figure 18 shows that P134 CAR-T cells inhibit tumor growth in a melanoma A375 cell NPG mouse subcutaneous xenograft model; Figure 19 shows that P134 CAR-T cells inhibit tumor growth in a breast cancer MDA-MB-468 cell NPG mouse subcutaneous xenograft model.

[0075] Figure 20 shows the systemic distribution of P134 CAR-T cells after intracranial injection. Detailed Implementation

[0076] The embodiments described are provided to better illustrate the present invention, but are not intended to limit the scope of the invention to the embodiments described. Therefore, non-essential improvements and adjustments made to the embodiments by those skilled in the art based on the above description are still within the scope of protection of the present invention.

[0077] Example 1: Construction and Preparation of Plasmid Vectors

[0078] This invention designs several groups of chimeric antigen receptor molecules, namely:

[0079] P131: Composed of CD44 single-chain antibody, CD133 single-chain antibody, CD8α hinge, CD8α transmembrane region, truncated portion of CD28 and IL-7Rα, and CD3ζ, with (GGGGS)2 as the linker. The amino acid sequence is shown in SEQ ID NO: 25. The nucleotide sequence is shown in SEQ ID NO: 32. The amino acid sequence of the (GGGGS)2 linker molecule is shown in SEQ ID NO: 18.

[0080] P132: Composed of CD44 single-chain antibody, CD8α hinge, CD8α transmembrane region, truncated portion of CD28 and IL-7Rα, and CD3ζ, with (GGGGS)3 as the linker. The amino acid sequence is shown in SEQ ID NO: 26. The nucleotide sequence is shown in SEQ ID NO: 33. The amino acid sequence of the (GGGGS)3 linker molecule is shown in SEQ ID NO: 17.

[0081] P133: Composed of CD133 single-chain antibody, CD8α hinge, CD8α transmembrane region, CD28, truncated portion of IL-7Rα, and CD3ζ, with the linker selected as (GGGGS)3. The amino acid sequence is shown in SEQ ID NO: 27. The nucleotide sequence is shown in SEQ ID NO: 34.

[0082] P134: Composed of CD44 single-chain antibody, CD133 single-chain antibody, CD8α hinge, CD8α transmembrane region, CD28, truncated portion of IL-7Rα, and CD3ζ, with the linker selected as (GGGGS)3. The amino acid sequence is shown in SEQ ID NO: 28. The nucleotide sequence is shown in SEQ ID NO: 35.

[0083] P135: Composed of CD44 single-chain antibody, CD133 single-chain antibody, CD8α hinge, CD8α transmembrane region, CD28, and CD3ζ, with the linker selected as (GGGGS)3. The amino acid sequence is shown in SEQ ID NO: 29. The nucleotide sequence is shown in SEQ ID NO: 36.

[0084] P136: Composed of CD44 single-chain antibody, CD133 single-chain antibody, CD8α hinge, CD8α transmembrane region, CD28, full-length IL-7Rα sequence, and CD3ζ, with (GGGGS)3 as the linker. The amino acid sequence is shown in SEQ ID NO: 30. The nucleotide sequence is shown in SEQ ID NO: 37.

[0085] P137 cells: Mock-T cells.

[0086] The structural diagram is shown in Figure 1.

[0087] The target genes P131, P132, P133, P134, P135, and P136 were synthesized and then ligated to a vector via restriction enzyme sites NotI and ScaI to form a circular plasmid vector, which was then transformed into Stbls bacteria.

[0088] The packaging plasmids pMDL, pMD2.G, and pREV were obtained through commercial purchase and named P001 plasmid, P002 plasmid, and P003 plasmid, respectively.

[0089] The plasmid production process, taking P134 as an example, uses the same process for all other plasmids:

[0090] 1. Upstream fermentation

[0091] (1) Seed preparation: Take out one P134 / Stbl3 / WCB glycerol bacteria, take out 100ul and inoculate it into 100ml LB liquid medium under 37℃ water bath conditions, and culture at 37℃ and 200rpm until the OD600 is between 1.5 and 1.8.

[0092] (2) Scale-up culture: Transfer the above seeds to a fermenter and culture for about 14-16 hours. Measure the OD600 value and end the culture.

[0093] 2. Downstream pyrolysis

[0094] (1) Fermentation broth replacement: Use a 500KD hollow fiber column to replace the fermentation broth after fermentation is completed, and use 5 times the weight of alkaline lysis buffer 1 to control the cell count at 50-150g / L.

[0095] (2) Cell lysis: The cells were lysed using a peristaltic pump at a flow rate of 500 mL / min.

[0096] (3) Clarification filtration and ultrafiltration liquid replacement 1: Adding 5M calcium chloride can easily make the final concentration of calcium chloride 1M. After standing for 24 hours, use two-stage Nennis filters in series for clarification filtration with pore sizes of 40um and 1.0 / 0.65um.

[0097] 3. Downstream purification

[0098] (1) Gel filtration chromatography: The chromatography column is 35 cm high, 50 mm in diameter, and has a volume of 686.9 mL. Follow the recommended procedure for the chromatography column.

[0099] (2) Affinity chromatography: The column height is 9.5 cm, the diameter is 6.6 mm, and the volume is 3.35 mL. Follow the recommended procedure for the column.

[0100] (3) Ultrafiltrate 2 and sterile filtration: using 50KD, 115cm 2 The hollow confinement column was used to replace the sample buffer solution after two stages of chromatography with the final product buffer solution at pH 7.5, with a replacement ratio of ≥7 times. Finally, ultrafiltration was performed, and the sample concentration was adjusted to 1.00±0.2 mg / ml. After ultrafiltration and buffer replacement 2, the final product was filtered using a sterile filter.

[0101] 4. Quality Control

[0102] The final plasmid product underwent quality control measures including appearance, pH value, restriction enzyme digestion pattern, concentration, A260 / A280 ratio, supercoil ratio, host DNA residue, host RNA residue, host protein residue, bacterial endotoxin, aseptic properties, and sequencing. The final plasmid product has been obtained and meets the requirements for subsequent processes.

[0103] Example 2: Preparation of Lentiviral Vector

[0104] The lentivirus production process, taking P134 as an example, uses the same process for all other lentiviruses:

[0105] 1. Upstream Packaging

[0106] (1) Take one 293 cell line, revive it in a 37°C water bath, count the cells after centrifugation, and culture it at a density of 500,000 cells per 30 ml volume, and record it as D0.

[0107] (2)D3, the cells were scaled up to a density of 500,000 cells and cultured in 60ml volume for a longer period.

[0108] (3)D6, the cells were enlarged to a density of 500,000 cells, cultured in 120ml volume, and cultured for a longer period.

[0109] (4)D9, cell culture was scaled up to a density of 500,000 cells per 300 ml culture volume and cultured for a longer period.

[0110] (5)D12, cell amplification culture to 500,000 cell density, 1000 ml culture medium volume.

[0111] (6) D13, mix the target gene plasmid p134, packaging plasmids P001, P002 and P003 in a certain volume ratio and let stand for 10 min, then mix with an equal volume of PEI transfection reagent and let stand for 15 min.

[0112] (7) Transfection: Slowly add the transfection reagent to the cell sap while shaking to spread the transfection reagent quickly.

[0113] (8) Add the promoter within 18-24 hours to increase lentivirus production.

[0114] (9) The culture is terminated after one week of culture.

[0115] 2. Downstream clarification, concentration and purification

[0116] (1) 1500g, centrifuged for 30min to remove cell precipitate.

[0117] (2) Filter the supernatant using a 0.45µm Nyssen filter.

[0118] (3) Filter the supernatant using a 0.2µm Nyssen filter.

[0119] (4) Purification and filtration by chromatography using a chromatography column.

[0120] (5) Sterility has been achieved by using a series of 0.45um + 0.2um Nysso filters.

[0121] 3 Quality Control

[0122] According to the "Key Considerations for Pharmaceutical Research and Application Materials for Clinical Trials of Cell Therapy Products" issued by the National Center for Drug Evaluation in 2018, the quality standards for viral vectors should include: appearance, pH value, osmolality, CAR gene identification, viral titer (physicochemical and biological function assays), DNA residue, residual host DNA transfer (such as SV40, E1A, etc.), protein residue, BSA residue, nuclease residue, RCR / RCL, sterility, endotoxin, mycoplasma, and detection of exogenous viruses.

[0123] Example 3: Preparation of CAR-T cell samples

[0124] 1. Collect PBMCs and isolate T cells.

[0125] (1) Volunteer physical examination.

[0126] (2) Use a single apheresis machine to obtain PBMC cell fluid.

[0127] (3) Transported to the production site via cold chain at 2-8℃.

[0128] (4) T cells were separated from PBMCs using the Miltenyi cell separation device.

[0129] 2. T cell activation and transduction

[0130] (1) Cultured in a medium containing IL-2 and CD3 / CD28 activating elements.

[0131] (2) When cell viability is >80%, lentivirus transduction is performed at MOI=7.

[0132] (3) After transduction, the cells were statically cultured for 48 hours.

[0133] 3. CAR-T cell expansion

[0134] (1) Transfer to G-rex culture flasks and continue to scale up the culture.

[0135] (2) After 4-5 days of culture, the culture is ended.

[0136] 4. CAR-T cell cryopreservation

[0137] (1) Centrifuge to remove the supernatant.

[0138] (2) Cryopreserve cells at a rate of 40 million cells per vial, with a volume of 4 ml.

[0139] All CAR-T cell test results met the usage requirements. See Table 1.

[0140] Table 1. CAR-T cell detection results for each group

[0141] Example 4: Comparison of cell binding activities of P131 scFv-hFc and P134 scFv-hFc

[0142] [Objective] This embodiment is used to compare the ability of the antibody moiety (CD44 scFv-linker-CD133 scFv, which is further linked with hFc to test the cell binding activity with the target antigen, abbreviated as P134 scFv-hFc) in the P134 molecule and the antibody moiety (CD44 scFv-linker-CD133 scFv, which is further linked with hFc to test the cell binding activity with the target cells, abbreviated as P131 scFv-hFc) in the P131 molecule to recognize the target antigen.

[0143]

Methods

[0144]

Results

[0145] Table 2 Comparison of cell-binding activities of P131 scFv-hFc and P134 scFv-hFc

[0146] Example 5: Comparison of in vitro killing effects of P134 CAR-T cells and P131 CAR-T cells

[0147] [Objective] This embodiment is used to compare the in vitro killing activity of P134 CAR-T cells and P131 CAR-T cells against CD44&CD133 dual-target positive tumor cells H_CD133 Luc U-87MG or CD44 positive tumor cells Luc-U87 MG.

[0148]

Methods

[0149] [Results] As shown in Figures 3 and 4 and Table 3, P134 CAR-T cells significantly inhibited the in vitro proliferation of H_CD133 Luc U-87MG and Luc-U87 MG cells in a dose-dependent manner. Compared with P131 CAR-T cells, P134 CAR-T cells significantly enhanced the in vitro killing effect on both types of glioma cells (P<0.05).

[0150] Table 3. Inhibition rate of P134 CAR-T cells and P131 CAR-T cells on the proliferation of glioma cells.

[0151] Example 6: Target binding specificity of P134 scFv-hFc sequence

[0152] [Objective] This embodiment is used to evaluate the specific recognition function of the publicly available CAR-T cell P134 CAR recognition region.

[0153]

Methods

[0154]

Results

[0155] Example 7: In vitro killing effect of P134 CAR-T cells and activation of T cells

[0156] [Objective] This embodiment is used to compare the killing ability of P134 CAR-T cells, P132 CAR-T cells, P133 CAR-T cells, P135 CAR-T cells, P136 CAR-T cells, and P137 Mock-T cells against CD44 & CD133 positive glioma cells, as well as the activation ability of T cells after stimulation by target antigens.

[0157] [Methods] P134 CAR-T cells, P132, P133, P135, P136 CAR-T cells, P137 Mock-T cells, and H_CD133 Luc U-87MG were co-cultured with H_CD133 Luc U-87MG at effector-target ratios of 3:1, 1:1, 1:3, and 1:10 for 48 hours. The cold luminescence value was detected by a luciferase reporter gene assay kit, and the in vitro proliferation inhibition rate was calculated to evaluate the killing ability. The concentrations of IFN-γ and Granzyme B in the cell supernatant were detected by ELISA to evaluate the T cell activation ability.

[0158] [Results] As shown in Figure 6 and Table 4, the P134 CAR-T cells provided in this disclosure can significantly inhibit the in vitro proliferation of H_CD133 Luc U-87MG cells, achieving 100% killing effect at an effector-to-target ratio of 1:1, which is significantly superior to other control CAR-T cells (P<0.05). As shown in Figures 7 and 8 and Table 5, CAR-T cells are activated after stimulation by target cells, promoting the release of cytokines IFN-γ and Granzyme B. The release of cytokines IFN-γ and Granzyme B by P134 CAR-T cells at low effector-to-target ratios (3:1 and 10:1) is significantly higher than that of other control CAR-T cells (P<0.05).

[0159] Table 4. Inhibitory effects of each group on the in vitro proliferation of H_CD133 Luc U-87MG cells.

[0160] Table 5. Release of cytokines IFN-γ and Granzyme B in each group after stimulation by target cells.

[0161] Example 8: Co-incubation of P134 CAR-T cells with target cells promotes CAR-T cell proliferation.

[0162] [Objective] This embodiment is used to compare the proliferation capacity of P134 CAR-T cells, P132 CAR-T cells, P133 CAR-T cells, P135 CAR-T cells, P136 CAR-T cells, and P137 Mock-T cells after stimulation with CD44 & CD133 double-positive target cells.

[0163] [Methods] CAR-T cells from different groups were labeled with CFSE. After co-incubating CAR-T cells and target cells at a 1:1 ratio for 24, 96, and 168 h, CFSE fluorescence signals were collected by flow cytometry. The data were analyzed to obtain the number of cells at different passages and the proportion of relatively undifferentiated cells, and the proliferation index (PI) was calculated according to the following formula.

[0164] Where i represents the generation, and Ni represents the number of T cells in that generation.

[0165]

Results

[0166] Table 6. Indices of CAR-T cell proliferation promotion after co-incubation with target cells in each group

[0167] Example 9: P134 CAR-T cell in vitro killing and cytokine secretion are concentration- and time-dependent.

[0168] [Objective] This embodiment is used to evaluate the concentration- and time-dependent killing effect of P134 CAR-T cells on target cells in vitro, as well as the concentration- and time-dependent activation of T cells after stimulation by target cells.

[0169]

Methods

[0170] [Results] As shown in Figure 9 and Table 7, P134 CAR-T cells significantly inhibited the in vitro proliferation of H_CD133 Luc U-87MG cells in a time- and concentration-dependent manner, while P137 Mock T cells only showed a weak killing effect on H_CD133 Luc U-87MG cells after incubation with target cells at a 1:1 ratio for more than 24 hours. As shown in Figures 10 and 11 and Table 8, P137 Mock T cells released less cytokine after stimulation by tumor cells, while P134 CAR-T cells were activated after stimulation by target cells, promoting the release of large amounts of cytokines IFN-γ and Granzyme B. The activation ability of T cells also showed a time- and concentration-dependent effect.

[0171] Table 7. Inhibitory effects of two cell groups on the in vitro proliferation of H_CD133 Luc U-87MG cells.

[0172] Table 8. Release of cytokines IFN-γ and Granzyme B from two groups of cells after activation by target cells.

[0173] Example 10: P134-dependent inhibition of the growth of various solid tumors

[0174] [Objective] This embodiment is used to evaluate the exogenous killing ability of P134 CAR-T cells against CD44&CD133 double-positive and CD44 single-positive tumor cells.

[0175] [Methods] P134 cells were co-cultured with 9 CD44&CD133 double-positive, 12 CD44 single-positive, and 1 CD44&CD133 double-negative tumor cells at an effector-target ratio of 3:1 for 48 hours. Cell killing was detected by luciferase reporter gene assay kit, flow cytometry, or LDH reagent.

[0176] [Results] As shown in Table 9, P134 CAR-T cells exhibited cytotoxic activity against 21 tumor cell lines, including CD44 / CD133 positive and CD44-positive glioma, pancreatic cancer, prostate cancer, renal cancer, lung cancer, breast cancer, epidermal cancer, melanoma, ovarian cancer, cervical cancer, osteosarcoma, liver cancer, and colon cancer, with inhibition rates ranging from 42% to 100%. However, the cytotoxic effect against CD44 & CD133 double-negative MCF-7 cells was weaker, with an inhibition rate of 23%. This indicates that the P134 CAR-T cells provided in this publication possess target antigen-dependent in vitro cytotoxic activity, demonstrating significant cytotoxic activity against both CD44 / CD133 positive and CD44-positive tumor cells.

[0177] Table 9. Killing effect of P134 CAR-T cells on various cancer cells.

[0178] Human non-small cell lung cancer A549 and NCI-H1975, human breast cancer cells MDA-MB-231 and MDA-MB-468, and human melanoma A375 are highly invasive and have high migration ability, and are often used to construct brain metastasis models (Qu X, Ding T, Zhao H, et al. Epigenetic Regulation of RNF135 by LSD1 Promotes Stemness Maintenance and Brain Metastasis in Lung Adenocarcinoma[J].Environmental Toxicology,2024,39(12).DOI:10.1002 / tox.24407;Liu Z, Dong S, Liu M, et al.Experimental models for cancer brain metastasis[J].Cancer Pastoexiology and Therapy,2024(001):002.DOI:10.1016 / j.cpt.2023.10.005;Chulyong K, Ali Z, Zizhen Z, et al. EXTH-63. FOCUSED ULTRASOUND HYPERTHERMIA MEDI-ATED CONTROL OF THERMAL RESPONSIVE CAR T CELL ACTIVITY IN BR-EAST CANCER BRAIN ME TASTASIS[J]. Neuro-Oncology, 2024(Supplement_8):Supplement_8.DOI:10.1093 / neuonc / noae165.0993). In vitro studies confirmed that P134 CAR-T cells significantly inhibited the proliferation of human non-small cell lung cancer A549 and NCI-H1975, human breast cancer cells MDA-MB-231 and MDA-MB-468, and human melanoma A375 cells in vitro, demonstrating the potential of P134 CAR-T cells to treat brain metastases of lung cancer, breast cancer, and melanoma.

[0179] Example 11: In vivo anti-CD44+ single-target glioma effect of P134 CAR-T cells

[0180] [Objective] This embodiment uses an orthotopic xenograft model of glioma cells U-87MG-GFP-Luc to evaluate the in vivo antitumor activity of P134 CAR-T cells against an orthotopic xenograft model of CD44 single-positive glioma cells.

[0181] [Methods] NPG mice were orally inoculated with U-87MG-GFP-Luc glioma cells (2 × 10⁶ cells). 4 Only in situ tumor-bearing models were established; after tumor formation, 2×10⁶ P134 CAR-T cells were administered intratumorally. 6 The drug is administered once a week for a total of 3 times, or temozolomide 12.5 mg / kg is administered by gavage. Tumor fluorescence signals are detected using a small animal imaging system, and general clinical observation and animal weight measurement are performed.

[0182] [Results] 2 × 10 P134 CAR-T cells 6 The cells significantly inhibited tumor growth in the NPG mouse orthotopic xenograft model of human glioma U-87MG-GFP-Luc cells (Figure 12) and prolonged the survival of tumor-bearing mice (Figure 13), with a stronger tumor-inhibiting effect than the positive control drug temozolomide. The animals tolerated the drug well during administration and observation, and no drug-related GvHD or weight changes were observed (Figure 14).

[0183] Example 12: In vivo anti-CD44 & CD133 dual-target glioma effect of P134 CAR-T cells

[0184] [Objective] This embodiment uses an orthotopic xenograft model of H_CD133 Luc U-87MG glioma cells to evaluate the in vivo antitumor activity of P134CAR-T cells against an orthotopic xenograft model of CD44&CD133 double-positive glioma cells.

[0185] [Methods] NPG mice were orally inoculated with 1×10 H_CD133 Luc U-87MG glioma cells. 5 Cells / Only in situ tumor-bearing models were established. After tumor formation, the cells were divided into 4 groups: the solvent control group received intracranial injection of normal saline weekly for 3 weeks; the positive control group received temozolomide 15 mg / kg by gavage daily for 5 days; and the low- and high-dose test substance groups received P134 CAR-T cells 3 × 10⁶ cells / weekly via intracranial injection. 5 cells / only and 3×10 6 Tumors were treated with a small animal imaging system at 3 doses per cell. Tumor fluorescence signals were detected, and general clinical observation and animal weight measurement were performed.

[0186]

Results

[0187] Example 13: The effect of P134 CAR-T cells on melanoma brain metastases in vivo

[0188] [Objective] This embodiment uses a melanoma orthotopic brain xenograft model to evaluate the in vivo antitumor activity of P134 CAR-T cells against melanoma brain metastases.

[0189] [Methods] NPG mice were orthotopically inoculated with 1×10-10 melanoma A375-Luc cells. 5 Cells / Only an orthotopic brain tumor-bearing model was established. After tumor formation, the cells were divided into two groups: the solvent control group received intracranial injection of normal saline; the P134 CAR-T group received intracranial injection of 1×10⁶ P134 CAR-T cells. 6 cells / animal. Small animal imaging to detect tumor fluorescence signals.

[0190] [Results] Compared with the model group, a single intracranial administration of P134 CAR-T significantly inhibited the growth of human melanoma A375 brain orthotopic xenografts, suggesting that P134 CAR-T effectively inhibits melanoma brain metastases in vivo. Tumor fluorescence signal results are shown in Figure 17.

[0191] Example 14: The in vivo anti-melanoma effect of P134 CAR-T cells

[0192] [Objective] This embodiment uses a human melanoma cell A375 subcutaneous xenograft tumor model to evaluate the in vivo antitumor activity of P134 CAR-T cells against CD44 single-positive melanoma.

[0193] [Methods] NPG mice were subcutaneously inoculated with 2 × 10⁶ A375 melanoma cells. 6 Subcutaneous tumor-bearing models were established, and after tumor formation, the tumors were divided into four groups: the solvent control group received a single intratumoral injection of normal saline; the positive control group received intraperitoneal injections of cisplatin 3 mg / kg twice a week; and the low-dose and high-dose test drug groups received a single intratumoral injection of 1 × 10⁶ P134 CAR-T cells. 6cells / each and 1×10 7 cells / cell. Measure and record the major diameter (a) and minor diameter (b) of the tumor using vernier calipers, and calculate V using the formula V = 1 / 2 × a × b. 2 Calculate the tumor volume.

[0194] [Results] As shown in Figure 18, P134 CAR-T cells, after a single intratumoral administration of 10... 6 cells / each or 1×10 7 All cells / unit significantly inhibited tumor growth (P<0.05), suggesting that P134 CAR-T cells effectively inhibit melanoma growth in vivo.

[0195] Example 15: The in vivo anti-breast cancer effect of P134 CAR-T cells

[0196] [Objective] This embodiment is used to evaluate the in vivo antitumor activity of P134 CAR-T cells against CD44&CD133 positive subcutaneous xenografts of breast cancer.

[0197] [Methods] NCG mice were subcutaneously inoculated with 5 × 10⁵ MDA-MB-468 breast cancer cells. 6 Subcutaneous tumor-bearing models were established, and after tumor formation, the tumors were divided into four groups: the solvent control group received intratumoral injection of normal saline; the positive control group received intraperitoneal injection of paclitaxel 10 mg / kg weekly for a total of three times; and the low-dose and high-dose test drug groups received intratumoral injection of 1 × 10 P134 CAR-T cells weekly. 6 cells / each and 1×10 7 Each tumor cell was administered three times. The long diameter (a) and short diameter (b) of the tumor were measured and recorded using calipers. The value of V was calculated using the formula V = 1 / 2 × a × b. 2 Calculate the tumor volume.

[0198]

Results

[0199] Example 16: In vivo tissue distribution and cytokine release of P134 CAR-T cells

[0200] [Objective] This embodiment is used to evaluate the systemic distribution of P134 CAR-T cells and the release of cytokines in plasma after intracranial administration.

[0201] [Methods] NPG mice were orally inoculated with 2 × 10⁶ H_CD133 Luc U-87MG glioma cells.5 Cells / Only an orthotopic tumor-bearing model was established, and after tumor formation, 2×10 P134 CAR-T cells were administered orthotopically. 6 P134 CAR-T cell distribution was detected by quantitative real-time PCR, and IL-2, IL-4, IL-6, IL-10, IFN-γ, and TNF-α were detected using an MSD kit. Plasma, brain (injection site), brain (non-administered side), trigeminal nerve, eyeball and optic nerve, spinal cord, adrenal gland, heart, liver, lung, spleen, kidney, stomach, ileum, uterus / epididymis, and ovary / testis were collected at 3 h, D2, D3, D8, D11, D15, D22, and D29.

[0202] [Results] As shown in Figure 20, P134 CAR-T cells were mainly distributed at the administration site after intracranial administration, and were not detected at other sites. A small amount of IFN-γ was detected in plasma, and IL-6 was only detected 3 hours after administration. Other cytokines were not detected (Table 10), suggesting that P134 CAR-T cells are mainly distributed at the administration site after local administration, with a low risk of systemic cytokine release.

[0203] Table 10 Results of peripheral blood cytokine release from P134 CAR-T cells after intracranial injection

[0204] The amino acid and nucleotide information represented by the sequences in the sequence listing of this invention are as follows:

[0205] SEQ ID NO: 13(CD44 VH)

[0206] SEQ ID NO: 14(CD44 VL)

[0207] SEQ ID NO: 15(CD133 VH)

[0208] SEQ ID NO: 16(CD133 VL)

[0209] SEQ ID NO: 17 (linker 3 loop)

[0210] SEQ ID NO: 18 (linker 2 loop)

[0211] SEQ ID NO: 19(hinge)

[0212] SEQ ID NO: 20 (Transmembrane domain)

[0213] SEQ ID NO: 21(CD28)

[0214] SEQ ID NO: 22 (IL-7R full length)

[0215] SEQ ID NO: 23 (IL-7R truncated)

[0216] SEQ ID NO: 24(CD3ζ)

[0217] SEQ ID NO: 25(P131)

[0218] SEQ ID NO: 26(P132)

[0219] SEQ ID NO: 27(P133)

[0220] SEQ ID NO: 28(P134)

[0221] SEQ ID NO: 29(P135)

[0222] SEQ ID NO: 30(P136)

[0223] SEQ ID NO: 31 (signal peptide sequence)

[0224] SEQ ID NO: 32 (P131 nucleotide sequence)

[0225] SEQ ID NO: 33 (P132 nucleotide sequence)

[0226] SEQ ID NO: 34 (P133 nucleotide sequence)

[0227] SEQ ID NO: 35 (full sequence of P134 nucleotides)

[0228] SEQ ID NO: 36 (full sequence of P135 nucleotides)

[0229] SEQ ID NO: 37 (full sequence of P136 nucleotides)

Claims

A bispecific chimeric antigen receptor comprising a CD44 and CD133 binding domain, a hinge region, a transmembrane domain, one or more costimulatory domains, and a CD3 zeta signaling domain, wherein, The CD44 binding domain comprises: the amino acid sequence of the heavy chain complementarity determining region HCDR1 is set forth in SEQ ID NO: 1; the amino acid sequence of the heavy chain complementarity determining region HCDR2 is set forth in SEQ ID NO: 2; the amino acid sequence of the heavy chain complementarity determining region HCDR3 is set forth in SEQ ID NO: 3; the amino acid sequence of the light chain complementarity determining region LCDR1 is set forth in SEQ ID NO: 4; the amino acid sequence of the light chain complementarity determining region LCDR2 is set forth in SEQ ID NO: 5; the amino acid sequence of the light chain complementarity determining region LCDR3 is set forth in SEQ ID NO: 6; The CD133 binding domain comprises: the amino acid sequence of the heavy chain complementarity determining region HCDR1 is set forth in SEQ ID NO: 7; the amino acid sequence of the heavy chain complementarity determining region HCDR2 is set forth in SEQ ID NO: 8; the amino acid sequence of the heavy chain complementarity determining region HCDR3 is set forth in SEQ ID NO: 9; the amino acid sequence of the light chain complementarity determining region LCDR1 is set forth in SEQ ID NO: 10; the amino acid sequence of the light chain complementarity determining region LCDR2 is set forth in SEQ ID NO: 11; the amino acid sequence of the light chain complementarity determining region LCDR3 is set forth in SEQ ID NO:

12. The bispecific chimeric antigen receptor of claim 1, wherein, The hinge region is a CD8a hinge region, the amino acid sequence of which is set forth in SEQ ID NO:

19. The bispecific chimeric antigen receptor of claim 1, wherein, The transmembrane domain is a CD8a transmembrane region, the amino acid sequence of which is set forth in SEQ ID NO:

20. The bispecific chimeric antigen receptor of claim 1, wherein, The co-stimulatory domain is CD28, the amino acid sequence of which is set forth in SEQ ID NO:

21. The bispecific chimeric antigen receptor of claim 4, wherein, The co-stimulatory domain further comprises a truncated portion of IL-7Ra, the amino acid sequence of which is set forth in SEQ ID NO:

23. The bispecific chimeric antigen receptor of any one of claims 1-5, the amino acid sequence of which is set forth in SEQ ID NO: 28, or an amino acid sequence having 95-99% identity thereto. A nucleic acid molecule encoding the chimeric antigen receptor of claim 6, the nucleotide sequence of which is set forth in SEQ ID NO:

35. An expression vector comprising the nucleic acid molecule of claim 7. A genetically engineered immune cell expressing the bispecific chimeric antigen receptor of any one of claims 1-5. The genetically engineered immune cell of claim 9, wherein the immune cell can be selected from the group consisting of a T lymphocyte, an NK cell, a hematopoietic stem cell, a pluripotent stem cell, or an embryonic stem cell culture-differentiated immune cell, and further preferably a T lymphocyte. A pharmaceutical composition comprising the bispecific chimeric antigen receptor of any one of claims 1-6, or the nucleic acid molecule of claim 7, or the expression vector of claim 8, or the genetically engineered immune cell of any one of claims 9-10. Use of the bispecific chimeric antigen receptor according to any one of claims 1 to 6, or the nucleic acid molecule according to claim 7, or the expression vector according to claim 8, or the genetically engineered immune cell according to any one of claims 9 to 10 for the manufacture of a medicament for the treatment of an anti-CD44 and / or CD133 positive tumor. Use according to claim 12, wherein the tumor is a brain glioma. Use according to claim 12, wherein the tumor is a brain metastasis tumor.